Skip to main content

Moberg Pharma publishes audited interim report for the period July 2019 – September 2020

STOCKHOLM, November 27[th], 2020 – On November 10[th], 2020, Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) published its interim report for the period July 2019 – September 2020. The Company today publishes an audited interim report for the same period. The audit has not resulted in any adjustments to the financial numbers published on November 10[th], 2020.

The audit of the interim report has been carried out due to the contemplated rights issue in the Company and the prospectus that is being prepared in connection thereto. The audited interim report is available in Swedish on the Company’s website:

For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post:

Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post:

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).